{"database": "lobbying", "table": "lobbying_activities", "rows": [[2968066, "ca9daedc-8490-4013-a04f-77f35f04edf6", "Q1", "VAN SCOYOC ASSOCIATES", 39837, "ARUP LABORATORIES, INC.", 2023, "first_quarter", "MED", "H.R.2369, To amend the Federal Food, Drug, and Cosmetic Act with respect to in vitro clinical tests, and for other purposes, Diagnostic Lab Testing Laboratory Testing related issues Public Law 117-328, Consolidated Appropriations Act, FY2023, Lab Infrastructure issues; and Diagnostic Lab Testing related issues Clinical Laboratory Improvement Amendments (CLIA), generally Pandemic All Hazards Preparedness Act, generally Monitor CURES 2.0, Diagnostic Lab Testing issues", "HOUSE OF REPRESENTATIVES,SENATE", 0, 0, "2023-04-19T11:11:09-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["2968066"], "units": {}, "query_ms": 6.712417991366237, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}